U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. LANTIDRA
  1. Vaccines, Blood & Biologics

STN: 125734
Proper Name: donislecel-jujn
Tradename: LANTIDRA
Manufacturer: CellTrans Inc.

Indication:

  • the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.

Product Information

  • Package Insert - LANTIDRA
  • Demographic Subgroup Information – LANTIDRA
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

 

Back to Top